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rior Aspirin Use and Outcomes in Elderly
atients Hospitalized With Acute Myocardial Infarction
dward L. Portnay, MD,* JoAnne M. Foody, MD,* Saif S. Rathore, MPH,* Yongfei Wang, MS,*
rederick A. Masoudi, MD, MSPH,†‡§ Jeptha P. Curtis, MD,*
arlan M. Krumholz, MD, SM, FACC*¶#
ew Haven, Connecticut; and Aurora and Denver, Colorado
OBJECTIVES We sought to assess the association between prior aspirin use and mortality, all-cause
readmission, and condition-specific readmission at one month and six months in a national
sample of Medicare beneficiaries hospitalized with a confirmed myocardial infarction (MI).
BACKGROUND Prior aspirin use is considered a marker of higher risk in patients with MI, yet the prognostic
significance of this factor has been debated.
METHODS Medicare beneficiaries 65 years old hospitalized with MI were evaluated to determine
whether there was an association between prior aspirin use and mortality (n  118,992),
all-cause readmission, and condition-specific readmission (n  78,975) at one month and six
months.
RESULTS One-third of the patients (n  39,531, 33.2%) were using aspirin before admission. Those
with prior aspirin use had significantly lower mortality at one month (16.1% vs. 19.0%, p 
0.0001) and six months (24.7% vs. 27.5%, p  0.0001). After multivariable adjustment, prior
aspirin use was found to be associated with a lower risk of one-month (relative risk ratio 0.93,
95% confidence interval [CI] 0.90 to 0.96) and six-month mortality (hazard ratio 0.94, 95%
CI 0.91 to 0.96). Prior aspirin use tended to reduce all-cause or coronary artery disease
readmissions at one month or six months.
CONCLUSIONS Prior aspirin use is not a marker of increased mortality in patients 65 years old hospitalized
with MI. (J Am Coll Cardiol 2005;46:967–74) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.049Cardiology Foundation
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clthough prior aspirin use is considered a marker of
igher risk in acute myocardial infarction (MI) (1), the
rognostic significance of this factor has been debated.
everal studies have reported that patients who present
ith MI despite chronic aspirin use have a higher risk of
dverse short-term outcomes (1–10). These studies, how-
ver, were limited by their small size (3,4,7,9), lack of
etailed data on baseline characteristics (3–5,7,8,10), and
se of patients drawn from randomized controlled trial
opulations (1–3,6,8,10). In contrast, the Global Registry
f Acute Coronary Events (GRACE) trial found that
spirin use before admission was associated with less
evere presentation, fewer in-hospital complications, and
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08-AG01011. The analyses upon which this publication is based were performed aower adjusted risk of in-hospital mortality in patients
ith acute coronary syndromes (11). However, this study
as unable to ascertain if prior aspirin use was associated
ith a higher or lower risk of long-term adverse events or
ortality.
In view of these conflicting studies, we sought to assess
hether prior aspirin use was associated with short- and
ong-term mortality and readmission in a national sample of
lderly patients hospitalized in the U.S. with MI. We
pecifically sought to assess whether prior aspirin use re-
ected a marker of higher risk in elderly patients with MI or
as independently associated with patient outcomes after
ccounting for confounding characteristics.
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tudy sample. The Cooperative Cardiovascular Project,
escribed in detail elsewhere (12), was a national quality
mprovement initiative of the Health Care Financing Ad-
inistration (currently the Centers for Medicare & Med-
caid Services) to improve the quality of care for Medicare
eneficiaries with acute MI. The 234,769 patients in the
ohort constitute all fee-for-service Medicare beneficiaries
ho were discharged from nongovernmental acute care
ospitals in the U.S. with a primary discharge diagnosis of
cute MI (code 410.xx of the International Classification of
iseases, 9th Revision, Clinical Modification) (13) between
anuary 1994 and February 1996, excluding patients for
hom the hospitalization had been a readmission for acute
I (code 410.x2). Patients’ records were abstracted for
linical data including medical history, clinical presentation,
omorbid conditions, and medication use before admission.
We restricted our cohort to the initial admission of
atients 65 years of age with a confirmed MI, excluding
7,593 patients age 65 years because Medicare beneficia-
ies in this age group are not representative of the general
nder-age-65 population due to the selective criteria for
edicare coverage in the younger population, and 31,186
atients without a confirmed MI, defined as creatine kinase
CK)-MB level 5%, lactate dehydrogenase (LDH) level
1.5 times normal, and LDH-1 level LDH-2, or a two
imes increase of the CK level and evidence of MI on the
resenting electrocardiogram. If patients had more than one
dmission during the study time period, only the first
dmission was included to avoid having patients counted
ore than once. This approach excluded 23,773 admissions
rom the study sample. In addition, 34,409 patients who
ad been transferred to the study hospital were excluded
rom analysis. Because prior aspirin use was the focus of our
nalysis, we excluded 19,378 patients whose medical records
ere missing documentation of previous chronic medication
se. Patients with contraindications to aspirin use (allergy to
spirin, history of bleeding, current bleeding, or other
onditions associated with an increased risk of bleeding) (n
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
CI  confidence interval
CK  creatine kinase
CVA  cerebrovascular accident
HR  hazard ratio
LDH  lactate dehydrogenase
MI  myocardial infarction
NSTEMI  non–ST-segment elevation myocardial
infarction
PTCA  percutaneous transluminal coronary
angioplasty
RR  relative risk ratio23,520) were also excluded from analysis. We excluded b,617 patients with terminal illness because their treatment
efore admission may not have been oriented toward im-
roving survival, and thus likely did not incorporate aspirin
se. Patients with missing data for mortality (n  325) and
eadmission (n  8,740) were excluded from analysis. In
otal, 115,777 (49.3%) of the original 234,769 patients met
t least one criterion for exclusion; the 118,992 remaining
atients (50.7%) constituted our study cohort.
rior aspirin use. Patients were classified as using aspirin
efore admission if aspirin was included in the medical
ecord of chronic medications taken before admission.
spirin administered only in the ambulance or emergency
oom during admission was not considered to constitute
rior aspirin therapy.
utcomes. The primary outcomes were death at one and
ix months from the date of admission, as determined by
eview of the Medicare Enrollment Database (14). Second-
ry outcomes included all-cause readmission and readmis-
ions for acute MI, coronary artery disease (CAD), and
erebrovascular accident (CVA) at one and six months from
he date of discharge as determined by review of patients’
edicare Part A data. For the analysis of these secondary
utcomes, we excluded patients (n  40,017) who died
uring hospitalization or patients who were transferred out
o other acute care hospitals because the starting point for
hese analyses is hospital discharge.
tatistical analysis. We compared the demographic and
linical characteristics of patients who had used aspirin
efore admission and those who had not using chi-square
ests for categorical variables and t tests for continuous
ariables. These included patient demographics (age, gen-
er, race), clinical presentation (Killip class, left ventricular
jection fraction, systolic blood pressure, heart rate, creati-
ine, white blood cell count, hemoglobin, anterior MI,
trial fibrillation, Q-wave MI, ST-segment elevation MI,
ardiac arrest on admission, angina before admission),
edical history (hypertension, diabetes mellitus, MI, heart
ailure, current smoker, cerebrovascular disease, peripheral
ascular disease, peptic ulcer disease, percutaneous translu-
inal coronary angioplasty [PTCA], coronary artery bypass
raft surgery [CABG]), comorbid conditions (dementia,
hronic obstructive pulmonary disease), mobility, urinary
ontinence, admission from nursing home, and medications
efore admission (angiotensin-converting enzyme inhibi-
ors, diuretics, nonsteroidal anti-inflammatory drugs,
igoxin, nitrates, beta-blockers, calcium-channel blockers,
arfarin).
We compared crude rates of mortality, all-cause readmis-
ion, and cause-specific readmissions at one month and six
onths between patients using aspirin before admission and
hose who were not, using chi-square tests. To further assess
he association of prior aspirin use with outcomes, we
erformed multivariable analysis using logistic regression
nd Cox proportional hazards models. Factors were entered
s covariates in the models based on clinical judgment and
ivariate analysis. For one-month outcomes, we did logistic
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September 20, 2005:967–74 Aspirin Use and Outcomes in Elderly AMI Patientsegression analysis and converted the odds ratio into relative
isk ratio (RR) for better interpretability (15). In the
ultivariable Cox proportional models for mortality within
ix months of admission, we considered the days from
dmission to death as time variable and truncated at six
onths of admission. In the multivariable Cox proportional
odels for readmission (all-cause, acute MI, CAD, CVA)
ithin six months of discharge, we considered the days from
ischarge to the day of first readmission as time variable and
runcated at six months of discharge, and also censored at
he time of death for patients who died within six months of
ischarge and were not readmitted before death. These
odel analyses were repeated for all outcomes separately
nd adjusted for patients’ demographic characteristics, clin-
cal presentation, medical history, comorbidities, and other
rior medications. Analyses were repeated restricted to the
ollowing subgroups: the prescription of aspirin at discharge
yes/no/unknown); ST-segment elevation MI (yes/no)—
efined as those without documented ST-segment elevation
I, new left bundle branch block, or Q-wave MI; age is
75 years (yes/no).
In the analysis, we imputed missing as “no” for categorical
ariables with “yes/no” responses, and median for continu-
us variables. For a categorical variable with “yes/no”
esponses or a continuous variable with missing values more
han 5%, we created a dummy variable to represent the
issing values and included it in the model with the
orresponding variable. All categorical variables with “yes/
o” responses and all continuous variables in our analyses
ad fewer than 10% missing values. The missing values in a
ategorical variable with responses other than “yes/no” were
erged into the category of “unknown,” or a separate
ategory of “unknown” was added to the categorical variable;
ummy variables were created corresponding to each of the
ategories including “unknown” and then added into the
odel leaving one out as the reference group. All categorical
ariables with responses other than “yes/no” had fewer than
0% missing values except for left ventricular ejection
raction. The effect of aspirin use before admission on
utcomes was not very different among the multivariable
ox proportional regression analyses with different adjust-
ents. Accordingly, we only reported the results from the
odel with full adjustment of patients’ demographic char-
cteristics, clinical presentation, medical history, comorbidi-
ies, and other prior medications. In secondary analyses, we
xcluded patients who died during hospitalization or pa-
ients who were transferred out to other acute care hospitals
n  40,017) in order to assess outcomes from hospital
ischarge.
Statistical analyses were performed using SAS version 8.2
SAS Inc., Cary, North Carolina). Analysis of the Cooper-
tive Cardiovascular Project database was approved by the
ale University School of Medicine Human Investigation
ommittee. wESULTS
aseline characteristics. Approximately one-third of pa-
ients in the study cohort (n  39,531, 33.2%) were using
spirin before admission. These patients were, on average,
ounger than patients who had not used aspirin (Table 1). A
reater proportion of patients who used aspirin before
dmission were white, male, had a prior MI, documented
eripheral vascular disease, cerebrovascular disease, prior
oronary revascularization, and used angiotensin-converting
nzyme inhibitors, digoxin, nitrates, beta-blockers, and
alcium-channel blockers before admission compared with
atients who had not used aspirin before admission. In
ontrast, patients who had used aspirin before admission
ad lower rates of anterior MI, Q-wave MI, ST-segment
levation MI, diabetes, peptic ulcer disease, smoking, de-
entia, chronic obstructive pulmonary disease, difficulty
alking, urinary incontinence, and admission from a nurs-
ng home compared with patients who had not used aspirin
efore admission.
ortality. Patients with prior aspirin use had lower crude
ortality at one month (16.1% vs. 19.0%, p  0.0001) and
ix months (24.7% vs. 27.5%, p  0.0001) compared with
atients who had not used aspirin before admission (Table
). After multivariable adjustment, prior aspirin use re-
ained associated with a lower risk of one-month mortality
RR 0.93, 95% confidence interval [CI] 0.90 to 0.96) and
ix-month mortality (hazard ratio [HR] 0.94, 95% CI 0.91
o 0.96) (Table 3, Figs. 1 and 2).
eadmissions. Patients who used aspirin before admission
ad higher crude rates of readmission for acute MI (4.1% vs.
.8%, p  0.018 at one month; 10.5% vs. 9.0, p  0.001 at
ix months) and CVA (4.2% vs. 3.9%, p  0.028 at one
onth; 11.4% vs. 10.3%, p  0.001 at six months) but had
imilar rates of readmission for all causes (21.2% vs. 21.4%,
 0.5 at one month; 44.8% vs. 44.8%, p  0.9 at six
onths) and CAD (20.7% vs. 20.8%, p  0.7; 43.8% vs.
3.6%, p  0.5 at six months) compared with patients who
ere not using aspirin before admission (Table 2).
Most of these crude associations were attenuated after
ultivariable adjustment, including prior aspirin use and
eadmissions for all causes (RR 0.98, 95% CI 0.96 to 1.01),
cute MI (RR 1.04, 95% CI 0.97 to 1.11), CAD (RR 0.99,
5% CI 0.96 to 1.01), and CVA (RR 1.00, 95% CI 0.93 to
.07) at one month and readmission for all causes (HR 0.97,
5% CI 0.95 to 1.00), CAD (HR 0.98, 95% CI 0.95 to
.00), and CVA (HR 1.01, 95% CI 0.96 to 1.06) at six
onths. However, patients who had used aspirin before
dmission tended to have an increased risk of readmission
or acute MI at six months (HR 1.05, 95% CI 1.00 to 1.11)
Table 4, Figs. 1 and 2).
ubgroup analysis. Among the 37,537 patients who pre-
ented with non–ST-segment elevation MI (NSTEMI),
6.7% (n  13,779) had used aspirin before hospitalization.
s with the general population of patients, prior aspirin use
as associated with a trend toward improved adjusted
TD
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M
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Overall
(118,992)
n (%) or
Mean (SD)
Without ASA
(71,461)
n (%) or
Mean (SD)
With ASA
(39,531)
n (%) or
Mean (SD) p Value
emographic characteristics
Age 76.4 (7.3) 76.6 (7.4) 76.1 (7.2) 0.0001
Women 58,938 (49.5) 42,102 (53.0) 16,836 (42.6) 0.0001
Race 0.0001
White 107,308 (90.2) 70,743 (89.0) 36,565 (92.5)
Black 7,272 (6.1) 5,452 (6.9) 1,820 (4.6)
Other 4,412 (3.7) 3,266 (4.1) 1,146 (2.9)
linical presentation
Killip class 0.0001
I 60,211 (50.6) 39,795 (50.1) 20,416 (51.6)
II 14,370 (12.1) 9,646 (12.1) 4,724 (12.0)
III 41,863 (35.2) 28,138 (35.4) 13,725 (34.7)
IV 2,548 (2.1) 1,882 (2.4) 666 (1.7)
Left ventricular ejection fraction 0.0001
Unknown 15,082 (12.7) 10,139 (12.8) 4,943 (12.5)
20 36,542 (30.6) 24,522 (30.9) 11,930 (30.2)
20–39 22,802 (19.2) 14,987 (18.9) 7,815 (19.8)
40–54 2,036 (1.7) 1,387 (1.7) 649 (1.6)
55 42,620 (35.8) 28,426 (35.8) 14,194 (35.9)
Systolic blood pressure 145.40 (32.6) 145.1 (33.0) 146.0 (31.7) 0.0001
Heart rate 87.7 (24.2) 88.2 (24.4) 86.6 (23.9) 0.0001
Creatinine 1.3 (0.6) 1.3 (0.7) 1.3 (0.6) 0.05
White blood cell count 10.8 (4.3) 11.0 (4.4) 10.5 (4.1) 0.0001
Hemoglobin 13.6 (1.8) 13.5 (1.8) 13.6 (1.8) 0.0001
Anterior infarction 55,242 (46.4) 37,526 (47.2) 17,716 (44.8) 0.0001
Left bundle branch block 7,931 (6.7) 5,158 (6.5) 2,773 (7.0) 0.0006
Atrial fibrillation 11,138 (9.4) 7,822 (9.8) 3,316 (8.4) 0.0001
2nd- or 3rd-degree heart block 1,590 (1.3) 1,126 (1.4) 464 (1.2) 0.0006
Q-wave infarction 70,563 (59.3) 48,579 (61.1) 21,984 (55.6) 0.0001
ST-segment elevation infarction 33,979 (28.6) 23,804 (30.0) 10,175 (25.7) 0.0001
Cardiac arrest on admission 3,928 (3.3) 2,857 (3.6) 1,071 (2.7) 0.0001
Duration of symptoms before admission (h) 0.0001
Unknown 11,016 (9.3) 7,534 (9.5) 3,482 (8.8)
None 63,076 (53.0) 40,854 (51.4) 22,222 (56.2)
6 10,907 (9.2) 7,220 (9.1) 3,687 (9.3)
6–12 16,145 (13.6) 10,942 (13.8) 5,203 (13.2)
12 17,848 (15.0) 12,911 (16.2) 4,937 (12.5)
edical history
Hypertension 76,452 (64.2) 51,205 (64.4) 25,247 (63.9) 0.05
Diabetes mellitus 38,626 (32.5) 26,268 (33.1) 12,358 (31.3) 0.0001
Prior myocardial infarction 35,989 (30.2) 19,441 (24.5) 16,548 (41.9) 0.0001
Prior heart failure 25,622 (21.5) 16,979 (21.4) 8,643 (21.9) 0.05
Current smoker 16,742 (14.1) 11,607 (14.6) 5,135 (13.0) 0.0001
Cerebrovascular disease 16,586 (13.9) 9,842 (12.4) 6,744 (17.1) 0.0001
Peripheral vascular disease 12,820 (10.8) 7,611 (9.6) 5,209 (13.2) 0.0001
Peptic ulcer disease 12,738 (10.7) 8,918 (11.2) 3,820 (9.7) 0.0001
PTCA 8,254 (6.9) 3,253 (4.1) 5,011 (12.7) 0.0001
CABG 15,655 (13.2) 7,044 (8.9) 8,611 (21.8) 0.0001
omorbid conditions
Dementia 6,885 (5.8) 4,866 (6.1) 2,019 (5.1) 0.0001
COPD 24,034 (20.2) 16,878 (21.2) 7,156 (18.1) 0.0001
Mobility 0.0001
Unknown 3,062 (2.6) 2,189 (2.8) 873 (2.2)
Independent 94,346 (79.3) 62,242 (78.3) 32,104 (81.2)
Unable to walk independently 21,584 (18.1) 15,030 (18.9) 6,554 (16.6)
Urinary continence 0.0001
Unknown 2,544 (2.1) 1,857 (2.3) 687 (1.7)
Continent 108,158 (90.9) 71,674 (90.2) 36,484 (92.3)
Incontinent 8,290 (7.0) 5,930 (7.5) 2,360 (6.0)
Admitted from a nursing home 6,125 (5.1) 4,398 (5.5) 1,727 (4.4) 0.0001Continued on next page
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t six months (HR 0.95, 95% CI 0.91 to 1.00) (Table 3).
rior aspirin use among NSTEMI patients was not associ-
ted with readmissions for all causes (RR 0.96, 95% CI 0.92
o 1.01), acute MI (RR 1.04, 95% CI 0.93 to 1.17), CAD
RR 0.97, 95% CI 0.93 to 1.02), and CVA (HR 0.91, 95%
I 0.81 to 1.02) at one month. At six months, prior aspirin
se was independently associated with lower risk of read-
ission for all causes (HR 0.95, 95% CI 0.92 to 0.99) and
AD (HR 0.96, 95% CI 0.92 to 1.00), but not for acute MI
able 1 Continued
Overall
(118,992)
n (%) or
Mean (SD)
edications before admission
Angiotensin-converting enzyme 26,386 (22.2)
Diuretics 43,393 (36.5)
NSAID 16,368 (13.8)
Digoxin 24,621 (20.7)
Nitrates 44,920 (37.8)
Beta-blockers 22,000 (18.5)
Calcium-channel blockers 44,528 (37.4)
Warfarin 8,587 (7.2)
SA  aspirin; CABG  coronary artery bypass graft surgery; COPD  ch
TCA  percutaneous transluminal coronary angioplasty.
able 2. Outcomes and Use of ASA Before Admission
Overall
(118,992)
n (%)
Total (118,992)
ortality (from admission)
1-month 21,477 (18.0)
6-month 31,575 (26.5)
eadmissions (from discharge)* (78,975)
1-month: any cause 16,836 (21.3)
6-months: any cause 35,384 (44.8)
1-month: AMI 3,092 (3.9)
6-months: AMI 7,537 (9.5)
1-month: CAD 16,381 (20.7)
6-months: CAD 34,473 (43.7)
1-month: CVA 3,185 (4.0)
6-months: CVA 8,443 (10.7)
In Patients With
ortality (from admission)
1-month 4,883 (13.0)
6-month 8,409 (22.4)
eadmissions (from discharge)*
1-month: any cause 5,862 (22.0)
6-months: any cause 12,393 (46.6)
1-month: AMI 1,179 (4.4)
6-months: AMI 2,861 (10.8)
1-month: CAD 5,706 (21.4)
6-months: CAD 12,089 (45.4)
1-month: CVA 1,191 (4.5)
6-months: CVA 3,182 (12.0)Patients who were transferred out or died in the hospital were excluded for the outcomes
AMI  acute myocardial infarction; ASA  aspirin; CAD  coronary artery disease;HR 1.04, 95% CI 0.96 to 1.13) and CVA (HR 0.97, 95%
I 0.90 to 1.05) (Table 4).
Among the 61,455 patients with aspirin prescription at
ischarge, 38.9% (n  23,929) had used aspirin before
ospitalization. Prior use of aspirin in this group of patients
as not significantly associated with reduced risk of mor-
ality at one month (RR 0.98, 95% CI 0.89 to 1.08) and at
ix months (HR 1.00, 95% CI 0.95 to 1.05) (Table 3), and
ended to reduce the risk of readmissions for all causes (RR
.97, 95% CI 0.93 to 1.00) and CAD (RR 0.97, 95% CI
Without ASA
(71,461)
n (%) or
Mean (SD)
With ASA
(39,531)
n (%) or
Mean (SD) p Value
17,121 (21.5) 9,265 (23.4) 0.0001
29,423 (37.0) 13,970 (35.3) 0.0001
11,951 (15.0) 4,417 (11.2) 0.0001
16,301 (20.5) 8,320 (21.0) 0.03
25,020 (31.5) 19,900 (50.3) 0.0001
12,267 (15.4) 9,733 (24.6) 0.0001
26,515 (33.4) 18,013 (45.6) 0.0001
7,367 (9.3) 1,220 (3.1) 0.0001
obstructive pulmonary disease; NSAID  nonsteroidal anti-inflammatory drug;
Without ASA
(71,461)
n (%)
With ASA
(39,531)
n (%) p Value
15,096 (19.0) 6,381 (16.1) 0.0001
21,828 (27.5) 9,747 (24.7) 0.0001
(52,262) (26,661)
11,184 (21.4) 5,652 (21.2) 0.5325
23,446 (44.8) 11,938 (44.8) 0.8543
1,987 (3.8) 1,105 (4.1) 0.0184
4,729 (9.0) 2,808 (10.5) 0.001
10,868 (20.8) 5,513 (20.7) 0.7201
22,788 (43.6) 11,685 (43.8) 0.5188
2,052 (3.9) 1,133 (4.2) 0.0283
5,401 (10.3) 3,042 (11.4) 0.001
–ST-Segment Elevation MI (37,537)
3,175 (13.4) 1,708 (12.4) 0.007
5,459 (23.0) 2,950 (21.4) 0.0004
3,713 (22.1) 2,149 (21.9) 0.7959
7,898 (47.0) 4,495 (45.9) 0.0922
715 (4.3) 464 (4.7) 0.0631
1,715 (10.2) 1,146 (11.7) 0.0001
3,598 (21.4) 2,108 (21.5) 0.8048
7,678 (45.7) 4,411 (45.0) 0.3294
742 (4.4) 449 (4.6) 0.5120
1,975 (11.7) 1,207 (12.3) 0.1595Nonof readmission.
CVA  cerebrovascular accident.
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eadmission for acute MI (RR 1.06, 95% CI 0.97 to 1.16)
nd CVA (RR 1.02, 95% CI 0.93 to 1.12) at one month. At
ix months, prior aspirin use tended to reduce the risk of
eadmission for all causes (HR 0.97, 95% CI 0.95 to 1.00)
nd CAD (HR 0.98, 95% CI 0.95 to 1.01), but to increase
he risk of readmission for acute MI (HR 1.08, 95% CI 1.02
o 1.15) and CVA (HR 1.07, 95% CI 1.00 to 1.13) (Table 4).
ISCUSSION
revious studies (1–10) have reported that prior aspirin use
s a risk factor for poor outcomes in patients presenting with
cute coronary syndromes, and prior aspirin use has been
ncluded in risk scores (1). However, in our nationally
epresentative cohort of Medicare beneficiaries with con-
Table 3. Independent Effect of Aspirin Use Be
Description n Relat
Total 118,992
Aspirin at discharge
Unknown 27,715
No 29,982
Yes 61,455
ST-segment elevation MI
No 37,537
Yes 81,455
Age 75 yrs
No 63,835
Yes 53,157
*Subgroups stratified by prescription of aspirin at discharge,
CI  confidence interval; MI  myocardial infarction.
igure 1. Adjusted 30-day risk of death and readmission: relative risk ratio
nd its 95% confidence interval. AMI acute myocardial infarction; CAD
coronary artery disease; CVA  cerebrovascular accident.
a
rmed MI, after adjusting for demographic characteristics,
linical presentation, medical history, comorbidities, and
ther prior medications, aspirin use was associated with a
ower risk of death (at both one and six months). The rates
f readmission were not significantly associated with prior
spirin use at one month.
These results differ from those of previous studies that
ound prior aspirin use to be a marker for poor outcomes.
ubgroup analyses of large randomized controlled trials
1,2,8) have limited generalizability to the overall popula-
ion, specifically the elderly, because these trials target a
ounger, healthier population. Furthermore, although at-
empts were made in the cited trials to account for differ-
nces in baseline characteristics and MI extent, they were
nable to control for a broad range of comorbid conditions.
n a study based on the Thrombolysis In Myocardial
nfarction-11b (TIMI-11b) and the Efficacy and Safety of
Admission on Mortality*
1 Month
isk Ratio (95% CI)
6 Months
Hazard Ratio (95% CI)
(0.90–0.96) 0.94 (0.91–0.96)
(0.96–1.01) 0.95 (0.92–0.98)
(1.11–1.35) 1.07 (1.00–1.14)
(0.89–1.08) 1.00 (0.95–1.05)
(0.89–1.01) 0.95 (0.91–1.00)
(0.90–0.97) 0.93 (0.90–0.96)
(0.91–0.99) 0.95 (0.92–0.98)
(0.89–0.96) 0.90 (0.86–0.95)
gment elevation MI, and age 75 years.
igure 2. Adjusted six-month risk of death and readmission: hazard ratiofore
ive R
0.93
0.98
1.22
0.98
0.94
0.93
0.95
0.91nd its 95% confidence interval. AMI acute myocardial infarction; CAD
coronary artery disease; CVA  cerebrovascular accident.
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vents (ESSENCE) trials, aspirin use in the seven days
efore admission was associated with an almost two-fold
ncrease in the odds of the combined end point of all-cause
ortality, MI, or urgent revascularization (odds ratio 1.86,
5% CI 1.26 to 2.73) (1). This risk was greater than that for
ll other independent variables including age 65 years and
levated serum cardiac markers. While both of these trials
djusted for typical risk factors (age, gender, past medical
nd family history, and so on), other clinically relevant
actors such as renal failure, severe hypertension, planned
se of coronary intervention or fibrinolytic therapy, and
ther comorbid conditions (chronic obstructive pulmonary
isease, dementia, mobility, or urinary continence status)
ere either excluded from the trial or not included in the
isk adjustment. In an analysis of the Platelet Glycoprotein
Ib/IIIa in Unstable Angina: Receptor Suppression Using
ntegrilin Therapy (PURSUIT) trial, prior aspirin use was
ssociated with an increased likelihood of death or MI at 30
ays (odds ratio 1.16, 95% CI 1.00 to 1.33) and at 6
onths, although this did not reach statistical significance
t 6 months (odds ratio 1.14, 95% CI 0.98 to 1.33)
mong patients presenting with unstable angina/NSTEMI
2). In the Platelet Receptor Inhibition in Ischemic Syn-
rome Management in Patients Limited by Unstable Signs
nd Symptoms (PRISM-PLUS) trial, there was evidence of
oor outcomes in prior aspirin users (8). In contrast to these
tudies, our analysis of a community-based sample of
atients presenting with NSTEMI shows that prior aspirin
se is associated with a lower rate of mortality that was
able 4. Effect of ASA Use Before Admission on Readmission*
Description n All Cause
month, relative risk ratio (95% CI)
Total 78,975 0.98 (0.96–1
ASA at discharge
Unknown 2,810 1.02 (0.93–1
No 11,570 0.98 (0.93–1
Yes 53,429 0.97 (0.93–1
ST-segment elevation MI
No 26,606 0.96 (0.92–1
Yes 52,369 0.99 (0.96–1
Age 75 yrs
No 45,015 0.99 (0.95–1
Yes 33,960 0.98 (0.94–1
months, hazard ratio (95% CI)
Total 78,975 0.97 (0.95–1
ASA at discharge
Unknown 2,810 1.03 (0.90–1
No 11,570 0.97 (0.93–1
Yes 53,429 0.97 (0.95–1
ST-segment elevation MI
No 26,606 0.95 (0.92–0
Yes 52,369 0.98 (0.95–1
Age 75 yrs
No 45,015 0.98 (0.95–1
Yes 33,960 0.97 (0.93–1
Subgroups stratified by prescription of aspirin at discharge, ST-segment elevation M
ASA  aspirin; CAD  coronary artery disease; CI  confidence interval; CVAtatistically significant. wThe present study suggests that prior aspirin use is a
arker of a higher-risk patient. Prior aspirin users were
ore likely to be men and had more frequent medical
istories of vascular disease (prior MI, cerebrovascular
isease, PTCA, or CABG). The patients using aspirin
efore admission were also more likely to be using other
ardiac medications (beta-blockers, calcium-channel block-
rs, nitrates, and digoxin) before admission. The finding
hat aspirin use at discharge was more than 13% lower in the
roup that was not taking aspirin before admission may be
ecause patients taking a medication on admission are more
ikely to be discharged on it. However, admission aspirin use
as independently associated with reduced mortality even
fter adjusting for other cardiac medications. This finding
uggests that aspirin use is not solely a surrogate marker for
mproved quality of care.
In contrast to previous reports, our findings suggest that
rior aspirin use has a protective role in acute MI. While
ifferent than the findings of the large randomized con-
rolled trials, our findings corroborate those of multiple
maller studies that have shown that prior aspirin use affects
he presentation and severity of acute MI (5–7,9,11). For
xample, Col et al. (5) reported that patients taking aspirin
efore admission were more likely to have a non–Q-wave
nfarction (65% vs. 49%, odds ratio 1.91, p  0.001) and to
ustain a small MI compared with nonaspirin users (30% vs.
2%, odds ratio 1.57, p  0.001). In a study using more
ecent data, Spencer et al. (11) reported that in both patients
ith history of CAD and those without, prior aspirin use
MI CAD CVA
1.04 (0.97–1.11) 0.99 (0.96–1.01) 1.00 (0.93–1.07)
0.95 (0.77–1.19) 1.02 (0.93–1.12) 1.04 (0.84–1.30)
0.99 (0.87–1.13) 0.98 (0.93–1.04) 0.94 (0.83–1.08)
1.06 (0.97–1.16) 0.97 (0.93–1.00) 1.02 (0.93–1.12)
1.04 (0.93–1.17) 0.97 (0.93–1.02) 0.91 (0.81–1.02)
1.04 (0.95–1.13) 0.99 (0.96–1.03) 1.05 (0.96–1.15)
1.06 (0.97–1.16) 0.99 (0.95–1.02) 0.98 (0.90–1.07)
1.01 (0.90–1.13) 0.99 (0.94–1.03) 1.03 (0.92–1.14)
1.05 (1.00–1.11) 0.98 (0.95–1.00) 1.01 (0.96–1.06)
1.16 (0.87–1.54) 1.03 (0.90–1.18) 1.00 (0.78–1.29)
0.99 (0.89–1.09) 0.97 (0.92–1.02) 0.93 (0.84–1.02)
1.08 (1.02–1.15) 0.98 (0.95–1.01) 1.07 (1.00–1.13)
1.04 (0.96–1.13) 0.96 (0.92–1.00) 0.97 (0.90–1.05)
1.07 (1.00–1.14) 0.99 (0.96–1.02) 1.04 (0.98–1.10)
1.06 (1.00–1.13) 0.98 (0.95–1.01) 1.03 (0.97–1.09)
1.04 (0.95–1.13) 0.97 (0.93–1.01) 0.99 (0.92–1.07)
d age 75 years.
rebrovascular accident; MI myocardial infarction..01)
.12)
.03)
.00)
.01)
.03)
.02)
.03)
.00)
.17)
.02)
.00)
.99)
.01)
.01)
.00)as associated with a significant reduction in the likelihood
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o 0.61 and odds ratio 0.35, 95% CI 0.3 to 0.4, respectively).
Certain issues should be considered in the interpretation
f our results. As an observational study based on retrospec-
ive chart review, our study is subject to the typical limita-
ions of this type of design. Despite our efforts to control for
onfounding variables, we could not exclude unmeasured
actors that may have affected the results. We defined prior
spirin use as the taking of aspirin before admission,
xcluding patients who received aspirin in the ambulance or
n the emergency department. Although we cannot com-
ent on the exact chronicity of aspirin use, we believe this
s a suitable definition for comparison to previous trials
here prior aspirin use was defined as aspirin use for at least
to 14 days before admission. Finally, we cannot comment
n the effects of aspirin dosage and outcomes. However,
iven the findings that dosages of 81 to 325 mg of aspirin
re effective in reducing events (16) and that most patients
reated with aspirin in 1993 to 1994 were probably treated
ith dosages within this range, these results are likely valid.
onclusions. In this nationally representative, community-
ased cohort of older patients, prior aspirin use was associated
ith a lower risk of death after presentation with acute MI.
his finding raises questions about the appropriateness of its
ncorporation as an independent variable into risk adjustment
odels.
ddress for correspondence: Dr. Harlan M. Krumholz, Yale
niversity School of Medicine, 333 Cedar Street, P.O. Box
08088, New Haven, Connecticut 06520. E-mail: harlan.
rumholz@yale.edu.
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